4-Nov-2025 4:23 PM CST - Business Wire Travere Therapeutics to Participate at Upcoming Investor Conferences Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET Stifel 2025 Healthcare Conference Wednesday, November 12, 2025 TD Cowen Immunology & Inflammation Summit Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET Jefferies Global Healthcare Conference Pr
30-Oct-2025 3:01 PM CST - Business Wire Travere Therapeutics Reports Third Quarter 2025 Financial Results Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update. We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confidence in FILSPARI among physicians and patients, said Eric Dube, Ph.D., president and chief executive of
23-Oct-2025 3:30 PM CST - Business Wire Travere Therapeutics to Report Third Quarter 2025 Financial Results Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Traveres website at https://ir.travere.com/events-and-presentation
6-Aug-2025 3:01 PM CST - Business Wire Travere Therapeutics Reports Second Quarter 2025 Financial Results Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its second quarter 2025 financial results and provided a corporate update. We continue to make strong progress against our strategic priorities, putting Travere on a trajectory for both near- and long-term growth. This quarter marked our strongest commercial performance to date, with increased momentum for FILSPARI resulting in significant growth in a dynamic IgAN market, said Eric Dube, Ph.D., president and
5-Aug-2025 3:30 PM CST - Business Wire Travere Therapeutics to Participate at Upcoming Investor Conferences Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET Citi's 2025 Biopharma Back to School Conference Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET 2025 Wells Fargo Healthcare Conference Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET Cantor Global
30-Jul-2025 3:30 PM CST - Business Wire Travere Therapeutics to Report Second Quarter 2025 Financial Results Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Traveres website at https://ir.travere.com/events-and-presentation
7-May-2025 3:30 PM CST - Business Wire Travere Therapeutics to Participate at Upcoming Investor Conferences #Inrareforlife--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare
1-May-2025 3:01 PM CST - Business Wire Travere Therapeutics Reports First Quarter 2025 Financial Results #1Q25earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update. As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the year reflects this leadership in the first quarter, we delivered 13% sequential net sales growth for FILSPARI in the U.S., driven by sustained d
24-Apr-2025 3:30 PM CST - Business Wire Travere Therapeutics to Report First Quarter 2025 Financial Results #1Q25Earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Traveres website at https://ir.travere.com/events-and-presentations. Fo
4-Nov-2025 4:23 PM CST - Business Wire Travere Therapeutics to Participate at Upcoming Investor Conferences Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET Stifel 2025 Healthcare Conference Wednesday, November 12, 2025 TD Cowen Immunology & Inflammation Summit Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET Jefferies Global Healthcare Conference Pr
30-Oct-2025 3:01 PM CST - Business Wire Travere Therapeutics Reports Third Quarter 2025 Financial Results Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update. We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confidence in FILSPARI among physicians and patients, said Eric Dube, Ph.D., president and chief executive of
23-Oct-2025 3:30 PM CST - Business Wire Travere Therapeutics to Report Third Quarter 2025 Financial Results Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Traveres website at https://ir.travere.com/events-and-presentation
6-Aug-2025 3:01 PM CST - Business Wire Travere Therapeutics Reports Second Quarter 2025 Financial Results Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its second quarter 2025 financial results and provided a corporate update. We continue to make strong progress against our strategic priorities, putting Travere on a trajectory for both near- and long-term growth. This quarter marked our strongest commercial performance to date, with increased momentum for FILSPARI resulting in significant growth in a dynamic IgAN market, said Eric Dube, Ph.D., president and
5-Aug-2025 3:30 PM CST - Business Wire Travere Therapeutics to Participate at Upcoming Investor Conferences Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET Citi's 2025 Biopharma Back to School Conference Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET 2025 Wells Fargo Healthcare Conference Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET Cantor Global
30-Jul-2025 3:30 PM CST - Business Wire Travere Therapeutics to Report Second Quarter 2025 Financial Results Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Traveres website at https://ir.travere.com/events-and-presentation
7-May-2025 3:30 PM CST - Business Wire Travere Therapeutics to Participate at Upcoming Investor Conferences #Inrareforlife--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare
1-May-2025 3:01 PM CST - Business Wire Travere Therapeutics Reports First Quarter 2025 Financial Results #1Q25earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update. As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the year reflects this leadership in the first quarter, we delivered 13% sequential net sales growth for FILSPARI in the U.S., driven by sustained d
24-Apr-2025 3:30 PM CST - Business Wire Travere Therapeutics to Report First Quarter 2025 Financial Results #1Q25Earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Traveres website at https://ir.travere.com/events-and-presentations. Fo
